Interstitial Pneumonia
12
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
17%
2 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
Ultrasound and Respiratory Physiological Signals in Lung Diseases
Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study
The Clinical Course of Interstitial Pneumonia With Autoimmune Features
Identification of Predictors for the Evolution of COVID-19 Related Pneumonia by Transcriptomic and Seroproteomic
Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients
Comparison Between Positive and Negative COVID-19 Pneumonia
Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +
The Effectiveness of Respiratory Tele-rehabilitation After COVID-19 Pneumonia Related: a Randomized Controlled Trial
Clinical Characteristics of Interstitial Pneumonia With Autoimmune Features (IPAF) - a Multicenter Prospective Study
Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy
Rituximab in Rheumatoid Arthritis Lung Disease
Case-Control Study of Fibrotic Interstitial Lung Disease (ILD) and Cardiac Disease / Interventions.